Kalaris Therapeutics Inc.
08/13/2025 | Press release | Distributed by Public on 08/13/2025 06:17
Proxy Results (Form 8-K)
| Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
Kalaris Therapeutics, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders on August 12, 2025. The following is a summary of the matters voted on at that meeting.
| 1. |
The stockholders of the Company elected Srinivas Akkaraju, M.D., Ph.D., and Andrew Oxtoby as Class II directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his respective successor has been duly elected and qualified. The results of the stockholders' vote with respect to such matter were as follows: |
| For | Withheld |
Broker Non- Votes |
||||||||||
|
Srinivas Akkaraju, M.D., Ph.D. |
14,626,646 | 144,695 | 1,328,348 | |||||||||
|
Andrew Oxtoby |
14,668,424 | 102,917 | 1,328,348 | |||||||||
| 2. |
The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the stockholders' vote with respect to such matter were as follows: |
|
For |
Against |
Abstain |
||
| 16,090,928 | 6,975 | 1,786 |
Kalaris Therapeutics Inc. published this content on August 13, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on August 13, 2025 at 12:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]